Drug Profile
TRX E 002 1
Alternative Names: Cantrixil; TRX-E-002-1; TRX1; TRXE002Latest Information Update: 27 Oct 2023
Price :
$50
*
At a glance
- Originator Novogen
- Developer Kazia Therapeutics
- Class Antineoplastics; Benzopyrans; Small molecules
- Mechanism of Action Electron transport chain complex protein inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Ovarian cancer
- No development reported Fallopian tube cancer; Peritoneal cancer
Most Recent Events
- 25 Oct 2023 TRX E 002 1 is still in phase-I development for Ovarian-cancer(Monotherapy, Combination therapy, Second-line therapy or greater) in USA and Australia (Intraperitoneal) (Vivesto pipeline, October 2023)
- 28 Apr 2022 No recent reports of development identified for phase-I development in Fallopian-tube-cancer(Combination therapy, Second-line therapy or greater) in Australia (Intraperitoneal)
- 28 Apr 2022 No recent reports of development identified for phase-I development in Fallopian-tube-cancer(Combination therapy, Second-line therapy or greater) in USA (Intraperitoneal)